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Abstract
The cardiac ryanodine receptor (RyR2) is a Ca2+ ion channel found in the sarcoplasmic
reticulum (SR), an intracellular membranous Ca2+ storage system. It is well known that a
destabilization of RyR2 can lead to a Ca2+ flux out of the SR, which results in an
overload of intracellular Ca2+; this can also lead to arrhythmias and heart failure. The
catecholamines play a large role in the regulation of RyR2; stimulation of the βadrenergic receptor on the cell membrane can lead to a hyperphosphorylation of RyR2,
making it more leaky to Ca2+. We have previously shown that strong electron donors will
inhibit RyR2. It is hypothesized that the catecholamines, sharing a similar structure with
other proven inhibitors of RyR2, will also inhibit RyR2. Here we confirm this hypothesis
and show for the first time that the catecholamines, isoproterenol and epinephrine, act as
strong electron donors and inhibit RyR2 activity at the single channel level. This data
suggests that the catecholamines can influence RyR2 activity at two levels. This offers
promising insight into the potential development of a new class of drugs to treat heart
failure and arrhythmia; ones that can both prevent the hyperphosphorylation of RyR2 by
blocking the β-adrenergic receptor, but can also directly inhibit the release of Ca2+ from
RyR2.
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Chapter I Introduction to Cardiac Muscle

1.1 Muscle
Muscles are the means by which animals move, maintain homeostasis, digest food,
breathe, and accomplish various other tasks essential to maintain life. Contraction of
muscle takes chemical energy and turns it into a force capable of doing mechanical work.
Muscle comes in both the voluntary and involuntary varieties, which together make up a
significant portion of an animal's mass. There are 3 classifications of muscle: skeletal,
cardiac, and smooth.

Both cardiac and skeletal muscles are known as striated muscle, due to the appearance of
striations in their structure. These striations are the contractile elements of the muscle
tissue, which appear as alternating dark and light bands when viewed under a
microscope. Skeletal is the only example of a voluntary muscle; animals control the
contraction via their nervous system. Cardiac and smooth are involuntary muscles.

Overlapping contractile proteins in striated muscle allow for a greater force and distance
of contraction; these are essential for physical movement of an animal and also for
generating enough force to pump blood through the body. Although skeletal and cardiac
muscles have similarities in their structure, they function through slightly different
mechanisms. Smooth muscle lacks the alternating pattern of light and dark contractile
elements; the seemingly random alignment of contractile proteins in smooth muscle
allows it to maintain its contraction for longer periods of time.
1

1.1.1

Cardiac Muscle

Cardiac muscle is involved in the contraction of the heart. The cells that make up the
muscle of the heart are referred to as cardiomyocytes. The main proteins making up the
cardiac muscle are actin and myosin; the interaction between these 2 proteins is what
leads to contraction in muscle (See Section 1.2.4). Thick filaments are made up of many
myosin molecules, forming a rod-like structure, with many myosin heads coming off the
filament. These myosin heads bind to the thin filaments made up from F-actin, troponin
and tropomyosin. The thin and thick filaments are overlapping in the muscle cell;
underneath a microscope, regions containing overlap between the thin and thick filaments
appear denser (A bands) and regions where just the thin filaments exist are lighter (I
bands). Z disks serve as anchors in the I bands, where all of the thin filaments are
attached.

Figure 1 Space filling model showing F-actin interacting with the thick filament's
myosin head1
2

The thin and thick elements together (sarcomere) give the muscle its striated appearance.
Long chains of sarcomeres are referred to as myofibrils; many of these myofibrils
together are what is known as a muscle fiber.

The sarcolemma, or cell membrane, encompasses the muscle fiber. The sarcolemma is
responsible for maintaining electrochemical gradients between the cytosol and the
extracellular fluid. It is these electrochemical differences that are the driving force for the
action potential and muscle contraction.

The transverse tubules (T-tubules) are invaginations in the sarcolemma; they are typically
perpendicular to the muscle fibers. The primary purpose of the T-tubule is to allow the
action potential to propogate into the inner regions of the muscle fiber, and to activate Ltype Ca2+ channels. The T-tubules in cardiac muscle tend to be larger and fewer in
number than those found in skeletal muscle. In skeletal muscle the T-tubules are spaced
at about 1.2µm intervals, whereas in cardiac they are at 2.5µm intervals2.

3

Figure 2 Illustration showing the structure of muscle fibers1

1.2 The Calcium Release Channel

1.2.1 The Sarcoplasmic Reticulum
Sarcoplasmic Reticulum (SR) is a subcellular organelle whose primary role is to control
the levels of calcium in muscle cells. The SR runs along each myofibril and wraps around
it. There is a region of enlargement in the SR where it meets the T-tuble, known as the
terminal cisternae. A difference between skeletal and cardiac muscle is that in skeletal
muscle, the T-tubules overlap 2 terminal cisternae, creating a triadic junction, whereas
with cardiac muscle, the T-tubule is opposed to one terminal cisternae, creating a dyadic
junction.

4

Two different types of SR can be classified: the longitudinal SR (LSR), which runs along
the myofibril and junctional SR (JSR), the SR that forms the terminal cisternae and
makes a dyad or triad with the T-tubule system. The mixture of the 2 types of SR we
refer to as crude SR (CSR).

There are various proteins found both in the lumen of the SR, as well as membrane of the
SR. The 2 main proteins responsible for calcium entering and exiting the SR lumen are
the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, and the calcium release
channel. Ninety percent of the calcium pump is found in the longitudinal SR, whereas the
highest density of release channel is found in the junctional SR. There is approximately
one hundred times as much Ca2+ pump found in the SR than there is Ca2+ release channel.

1.2.2 The Calcium Release Channel
The calcium release channel is commonly known as the ryanodine receptor (RyR),
because of its high affinity for the plant alkaloid ryanodine when the channel is in its
open state3. It is the largest known ion channel, with around 5,000 amino acids and a
molecular weight around 2.3 MDa. It is comprised of 4 identical monomers, each of
molecular weight 565 kDa, which together form a homotetramer.

There are three different isoforms of RyR which are found in many places in the body;
however, each isoform is typically correlated to one of the three types of muscle. RyR1 is
5

primarily associated with skeletal muscle, RyR2 with cardiac muscle, and RyR3 with
smooth muscle. The three isoforms share approximately a 70% sequence homology,
leading to near identical three-dimensional structures.

The ryanodine receptor’s three-dimensional structure was first determined by cryoelectron microscopy methods in the mid-1990s4. Reconstructions of the 3 isomers show
similar structure overall. There are 2 main pieces associated with the channel: A large
cytoplasmic assembly, which consists of 4 identical monomers, each of which has been
hypothesized to have at least fourteen distinct domains5. The cytoplasmic assembly is
290x290Å looking from the top down, and 130Å thick. The second piece consists of a
smaller, transmembrane assembly (TA). The TA is imbedded in the SR and connects the
cytoplasm to the lumen inside of the SR; it measures 120x120x70Å.

6

Figure 3 Cryo-EM 3D reconstruction of RyR1 in both the open and closed states6

7

The calcium release channel is imbedded in the SR membrane and is responsible for
release of calcium ions from the lumen of the SR. Cryo-electron microscopy has shown
large domain changes between the open and closed states of the channel as seen in figure
3.; it has also been a useful tool in determining binding locations for many of the
molecules and proteins which interact with the channel.

1.2.2.1 Associated Proteins with the Ryanodine Receptor
FKBP 12: Primarily associated with RyR1, but also found in RyR2. It has a molecular
mass of 12kDa and is found at concentrations 10x that of FKP12.6. FKBP12 stabilizes
the closed conformation of RyR7. Removal of the FKBP has been shown to increase
subconductance states in bilayer studies in both RyR1 and RyR28.
FKBP12.6: Primarily associated with RyR2. It has a molecular mass of 12.6 kDa.
Although FKBP12.6 is found at much lower concentrations than FKBP12, RyR2 has
approximately a 500 fold greater affinity for it.
Calmodulin (CaM): A 16.8 kDa Ca2+-binding protein, capable of binding four Ca2+ ions,
two in each of its domains. In RyR1 CaM will stimulate the channel at low Ca2+
concentrations and inhibit at higher Ca2+ concentrations. In RyR2 CaM has only shown
channel inhibition9. Recent studies have shown that mutant variations of CaM, that can
exist in its Apo-CaM state (without Ca2+) even at high levels of Ca2+, binds in different
domains than that of Ca2+-bound CaM10. This may account for the discrepancies in
function between the two isoforms of RyR.

8

Protein Kinase A (PKA): A 96 kDa protein anchored to RyR2. It plays a role in the
phosphorylation of the channel, leading to a more open or closed state.
Junctin: A 26 kDa protein found in the junctional SR in both skeletal and cardiac
muscle. Junctin can bind to the RyR and couple to calsequestrin.
Triadin: A 35 kDa protein found in the junctional SR. Triadin plays a similar role to
junctin in coupling to calsequestrin. It has also been shown that both triadin and junctin
bind calsequestrin more strongly in the presence of low Ca2+11.
Calsequestrin (CSQ): A 45 kDa Ca2+-binding protein. It is found in the lumen of the SR
and each molecule of CSQ binds up to 50 Ca2+ ions with ow affinity (Kd∿1mM)12. By
binding large amounts of Ca2+, the SR is made a much better storage system for Ca2+ than
would otherwise be possible.
The Dihydropyridine Receptor (DHPR): A 100 kDa L-type voltage-gated Ca2+
channel. It is found embedded in the T-tubule membrane and plays a key role in
excitation-contraction coupling (See section 1.2.3). It makes direct contact with RyR1
and is essential to its function. The association between the DHPR and RyR2 is not as
well defined.
PP1 and PP2A: Phosphatases associated with RyR2.
Selenoprotein N: Appears to be responsible for sensing the cellular redox environment
and controlling the gating of RyR113.

9

1.2.2.2 Other Modulators of the Ryanodine Receptor
Calcium (Ca2+): The most crucial ion associated with the receptor. Calcium has a
biphasic effect upon the RyR. At low Ca2+ concentrations (<1µM), Ca2+ stimulates the
release of Ca2+ from RyR, a process referred to as calcium-induced calcium release
(CICR). At higher concentrations of Ca2+ (>100µM) the RyR is inhibited8. This biphasic
effect is attributed to there being several binding locations for Ca2+ on the receptor; one
which stimulates the channel and has a higher affinity for Ca2+, this is the primary
binding site at low Ca2+. A second binding site, which inhibits when bound with Ca2+, has
a much lower affinity so it is only populated at higher concentrations of Ca2+.
Magnesium (Mg2+): An inhibitor of RyR, believed to compete with high affinity Ca2+
binding sites14.
Glutathione (GSH): Plays a role in maintaining the redox status of cells. When an
excess of reactive oxygen species is present, GSH can donate electrons to hydroperoxide
resulting in a glutathione disulfide (GSSG) being formed. The ratio between GSH and
GSSG play a role in the state of RyR15.
Adenosine-5’-triphosphate (ATP): ATP along with other adenine nucleotides (cAMP,
ADP, and AMP) are stimulators of RyR16.

1.2.3 Excitation-Contraction Coupling
All cells in the animal kingdom, including muscle cells, are electrically polarized. The
electrical potential generated by the imbalance of charge on ions between the inside and
outside of the cell is referred to as the membrane potential. In some cells, when a set
10

membrane potential is reached (threshold potential), the cell will rapidly depolarize; in
muscle cells this leads to contraction. The process of an electrical signal being converted
into a mechanical response is referred to as excitation-contraction coupling (ECC).

The mechanism of EC coupling is slightly different in skeletal and cardiac muscle. The
difference arises from skeletal RyRs having a direct physical interaction with the DHPR.
Here only cardiac EC coupling will be discussed.

In the heart, pacemaker cells first initiate an action potential. The action potential travels
down the t-tubules which allow a threshold potential to be reached. This threshold
potential depolarizes the cell allowing for an influx of Ca2+ through the DHP receptors.
This influx of Ca2+, along with the close proximity of DHPRs to RyR2 initiates CICR.
This generates a positive feedback system allowing for more and more Ca2+ to be
released from the SR.

1.2.4 Contraction of Muscle
Once Ca2+ floods the cell upon release from the SR, troponin C, a Ca2+-binding protein
attached to the F-actin thin filaments, binds Ca2+. Upon binding of Ca2+ a conformational
change occurs on troponin C, this allows the myosin head to attach itself to the actin
filament.

11

ATP binds to the myosin head and the myosin dissociates itself from the actin filament.
ATP hydrolysis occurs, generating ADP and inorganic phosphate (Pi), as well as a
conformational change in the myosin head. The myosin head shifts its position further
down the actin filament and rebinds. Upon the binding of the myosin head to the actin
filament, Pi is released. Finally, the myosin head returns back to its resting state and
releases the ADP. This final step shifts the actin and myosin filaments relative to one
another causing muscle contraction. This can be visualized under the microscope; upon
muscle contraction, the Z disks will shift closer to one another. Skeletal muscle
contraction occurs on the order of 2-5ms, while cardiac muscle contracts between 2050ms.

1.2.5 Heart Failure and Arrhythmias Associated with RyR2
Heart failure (HF) is the heart’s inability to pump sufficient blood through the body to
supply the organs with enough oxygen. It was reported in 2012 that approximately 5.7
million people living in the United States are living with heart failure17. Of these, half of
them die within 5 years of the diagnosis. With such a high population of people being
affected by failure, it is important to understand the mechanisms under which heart
failure occurs, in order to both prevent and treat the disease.
It is known that electrical instabilities in cardiac muscle is what leads to the arrhythmias,
but how and why this occurs is still not completely understood. It has been shown that
there is a strong correlation between the improper handling of intracellular Ca2+ and HF.
12

Improper cardiac contraction via a malfunctioning RyR2 leads to a leak in Ca2+ during
diastole. The leak causes a change in the normal polarization of the cardiomyocyte,
altering the action potential in what is referred to as a delayed afterdepolarization (DAD).
DADs lead to arrhythmias and in turn sudden cardiac death (SCD).
Reduced cardiac output during HF is compensated for in the body by an elevation in the
body’s catecholamine levels18. Elevated catecholamine levels, while increasing cardiac
output, can worsen HF19. The catecholamines act indirectly on intracellular Ca2+
handling, triggering a receptor outside the cell, which in turn leads to a
hyperphosphorylation of the channel (See Chapter 2).
One hypothesis on how this hyperphosphorylation leads to a malfunctioning RyR2 has to
do with the FK binding proteins associated with RyR2. Phosphorylation of the channel
causes the FKBP12.6 to dissociate (although this remains controversial20), which
destabilizes RyR221. This is likely due to an increased Ca2+-dependent activation22.
Increased intracellular Ca2+ is not only due to the leak of Ca2+ from RyR2, but the
SERCA pump found in cardiac SR also has reduced function. During HF,
phospholamban (PLB), a membrane protein associated with RyR2, becomes hypophosphorylated. When PLB becomes hypo-phosphorylated it inhibits the pump’s
function. This along with the RyR2 leak leads to an increase in intracellular Ca2+ levels,
and affects contractility23,24.
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1.2.5.1 Catecholaminergic Polymorphic Ventricular Tachycardia
Catecholamines not only play a role in individuals with HF, but they play an especially
important role in individuals with catecholaminergic polymorphic ventricular tachycardia
(CPVT). During the “Fight-or-Flight Response,” elevated catecholamines increase heart
rate, the strength contraction of the heart, and increased airflow to the lungs, in the
presence of perceived danger. Under normal conditions this response is an evolutionary
advantage; however, these elevated catecholamine levels in individuals (CPVT), a
genetic disease involving a mutation on either RyR2 (CPVT1) or the associated protein
calsequestrin (CPVT2), can lead to arrhythmias and heart failure. CPVT is typically
treated with antagonists of the β-adrenergic Receptor (β-Blockers), such as carvedilol;
these compounds bind to the β-adrenergic receptor, preventing agonists of the receptor
from binding.

14

Chapter II Catecholamines

2.1 Introduction to Catecholamines
Catecholamines are an organic compound made up of 2 main parts; a benzene ring with 2
hydroxyl side groups referred to as a catechol, as well as an amine side chain. There are
both synthetic and naturally occurring catecholamines, all sharing a similar structure. In
the human body, the most abundant of the catecholamines include: epinephrine,
dopamine, and norepinephrine. This work will focus on the catecholamine epinephrine as
well as a non-natural catecholamine, isoproterenol, which shares a similar structure with
epinephrine.

2.2 Biosynthesis of Catecholamines
In the body, the first compound in the biosynthetic pathway is typically the amino acid Ltyrosine. In the liver, the process is started with phenylalanine being converted into
tyrosine. Tyrosine hydroxylase, an enzyme, uses molecular oxygen and tyrosine
substrates along with biopterin, a coenzyme, to add a hydroxyl group to L-tyrosine to
produce 3,4-dihydroxy-l-phenylalanine (l-DOPA). It is thought that tyrosine hydroxylase
provides the rate limiting step in the synthesis of catecholamines25.
The next step in the pathway is DOPA decarboxylase, often called aromatic L-amino acid
decarboxylase, converting L-DOPA into dopamine and CO2. Dopamine is the first of the
bodies catecholamines synthesized. For locations in the body such as the substantia nigra
and ventral tegmental area of the brainstem, the process stops here, so that dopamine can
be utilized.
15

Further along the pathway molecular oxygen and dopamine β-hydroxylase are used to
convert dopamine into norepinephrine. Regions of the body containing the dopamine βhydroxylase to make this conversion are referred to as, “noradrenergic.” Finally,
norepinephrine gains a methyl group from S-adenosylmethionine, being catalyzed by
phenylethanolamine N-methylTransferase, yielding epinephrine and homocysteine. The
phenylethanolamine N-methylTransferase is found in several locations of the body
including neurons in the brainstem and in adrenal cells.

16

Figure 4 Biosynthesis of Catecholamines26
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2. 3 Catecholamine Function in the Body
The catecholamines are often referred to as beta-adrenergic agonists due to their
activation of the beta-adrenergic receptor, a G protein-coupled receptor located on the
cellular membrane. There are three types of Beta-adrenergic receptors: β1, β2, and β3. β1
receptors are found primarily in cardiac muscle, but are also found in kidney and stomach
tissue. When the β1-adrenergic receptor is activated it activates adenylyl cyclase activity
within the cell, which in turn stimulates calcium release from the ryanodine receptor
thereby causing cardiac muscle contraction. The β2-adrenergic receptor is found
primarily in smooth muscle. When activated, β2-receptors also stimulate adenyl cyclase
activity; however, in smooth muscle this lowers the intracellular calcium levels, thereby
causing the dilation of the muscle. The β3-adrenergic receptor is found primarily in
adipose tissue and plays a role in the regulation of thermogenesis, as well as lipolysis.

This thesis focuses on the role of catecholamines in cardiac tissue, therefore only the β1adrenergic receptor will be discussed in detail.

2.4 Stimulation of the β1-Adrenergic Receptor
The β1-adrengeric receptor is coupled to a G protein which spans the cellular membrane
of cardiac myocytes. When an agonist of this receptor, such as epinephrine, binds to the
receptor, it causes one of the G proteins subunits within the cell to activate adenylyl
cyclase. The adenylyl cyclase, once activated, catalyzes the conversion of ATP into 3’,5’18

cyclic AMP (cAMP). The elevated cAMP levels within the cell activate protein kinase A,
an intracellular enzyme whose activity depends upon the level of cAMP within the cell.
Protein kinase A, once activated, adds phosphate groups to other proteins in a process
p
known as phosphorylation; leading to hyperphosphorylation of RyR2.
Hyperphosphorylation of RyR2 leads to a more open state of the channel.

2.5 Studied Compounds

2.5.1 Epinephrine

Figure 5 Chemical structure of epinephrine

Epinephrine (adrenaline outside the U.S.
U.S.) was first discovered in 1895 in extracts from
the adrenal gland by Polish physiologist Napolean Cybulski. It can be synthesized in a
number of locations in the body including: the adrenal medulla, chromaffin cells, and
neurons in the central nervous system. The ability of epinephrine to be produced in one
part of the body and be utilized in another classifies it as a hormone.

19

Epinephrine is naturally occurring, with a molecular weight of 183.2g/mol and existing at
typical concentrations of a few nanomolar27. The half-life of epinephrine in blood plasma
is on the order of 2 minutes, but is constantly being produced. In the early 1900s
epinephrine was used as a bronchodilator in asthma patients. It is widely used in medical
fields to treat a number of conditions including cardiac arrest and anaphylaxis. This
compound increases the strength of contractions (positive inotrope) inside of the heart. It
also increases the heart rate (positive chronotrope).

Epinephrine’s effect on both the airways and heart makes it the key hormone in the
“fight-or-flight response.” This physiological reaction prepares one’s body to either flee,
or stay and fight in the presence of danger.

2.5.2 Isoproterenol

Figure 6 Chemical Structure of isoproterenol

Isoproterenol (Isoprenaline outside the U.S.) was developed in 1941 and is not found
naturally in the body. It has a molecular weight of 211.3g/mol. Like epinephrine,
isoproterenol is an agonist of the β-adrenergic receptor; however, unlike epinephrine it
20

does not stimulate the α-adrenergic receptors, which lead to vasoconstriction of the veins
and arteries; this made it an ideal drug for the treatment of asthma for a time before the
release of albuterol, which is more selective for the β2-adrenergic receptor, making it a
better treatment of the airways.

Isoproterenol has a biphasic half-life when administered to patients, with a first phase
lasting only a few minutes and a second phase lasting up to 5 hours. It can either be
administered intravenously or by aerosol to the body.

Isoproterenol is an activator of all three types of β-adrenergic receptors, the affinity of β1
and β2 for Isoproterenol is greater than that of epinephrine, β3 receptors share about an
equal affinity for the two catecholamines. Isoproterenol’s primary use in the medical field
is in its activation of the β1-adrenergic receptor, which aids in the treatment of
bradycardia (a heart rate below 60BPM). Isoproterenol acts as both a positive
chronotrope and positive inotrope in cardiac muscle.

21

Chapter III Methods and Materials

3.1 Materials

3.1.1 Cardiac SR Preparation
Sheep heart SR isolation follows a modified protocol from Williams 199028. Sheep hearts
were removed and rinsed of excess blood from anesthetized sheep. The sheep heart was
stored in an ice cold homogenization buffer containing: 300mM Sucrose, 10mM PIPES,
0.5mM PMSF, 1µg/mL Leupeptin at PH 7.4. Upon arrival to the laboratory the heart was
dissected in a cold room, the atria along with extra fatty tissue were discarded.

Half (approximately 40g) of the ventricles of the heart were cut into cm3 pieces and
placed into 500mL of the homogenization buffer. The pieces were homogenized in a
blender for 20 seconds at top speed, then for another 20 seconds after a 30 second wait
period. The rest of the heart was homogenized following the same process.

The homogenates were combined and poured into 6 Type-19 rotor tubes and were
centrifuged for 20 minutes at 9,000g in a Beckman Type-19 Rotor. The supernatant was
filtered through 2 layers of cheesecloth and poured into 6 Type-19 tubes and centrifuged
at 44,000g for 75 minutes in a Beckman Type-19 rotor. Supernatant was discarded and
the pellet was placed into a resuspension buffer containing: 400mM KCl, 300mM
Sucrose, 0.5mM MgCl2, .5mM CaCl2, .5mM EGTA, .5mM PMSF, 1µg/mL Leupeptin,
25mM PIPES at pH 7.0. The solution was all poured into one Type-60 centrifuge tube
22

and centrifuged at 50,000 rpms for 30 minutes. The pellet was collected and added to the
resuspension buffer. The solution was homogenized using a glass homogenizer and
stored in 300µL aliquots in liquid nitrogen until use in experiments.

3.1.2 Determination of Protein Concentration
Cardiac SR protein concentration is measured using the method developed by Kalckar29.
The protein backbone has a maximum absorbance peak at 230nm and the amino acids
tyrosine and tryptophan peak at 280nm. Using an Agilent 8453 UV-Visible
spectrophotometer, the absorbance at three wavelengths was measured. Using the
following two equations along with the absorbance at 260nm (to correct for nucleic
acids), protein concentration is determined:

[ SR ] mg / ml = 1.45( Abs 280 ) − 0.74( Abs 260 )

(eqn 3.1)

[ SR ] mg / ml = 0.185( Abs 230 ) − 0.075( Abs 260 )

(eqn 3.2)

3.2 Planar Lipid Bilayer
The majority of work in this thesis consists of work done incorporating SR vesicles into a
planar lipid bilayer. Incorporation of ion channels into artificial planar lipid bilayers
allows for the kinetics of single ion channels to be studied. It also provides an extremely
useful tool in studying how various compounds and proteins affect the gating of the
channel.
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3.2.1 Method
Two chambers, comprised of either acetyl or delrin, are separated by a 100-200µm
aperture. The aperture is created in one of three ways: by drilling with a 100-200µm drill
bit, sparking through the delrin or acetyl barrier between the chambers, or a combination
of drilling and sparking through the created aperture. The wall separating the two
chambers is on the order of the size of the aperture itself. It has been reported that having
a hole on the order of the wall size will help promote fusion of proteins into the planar
lipid bilayer30.

The two chambers are filled with an aqueous solution of unequal concentration and
volumes. The Trans (Luminal) chamber is filled with 650µL of buffer consisting of
25mM HEPES and 40mM CsMeSO4 at pH 7.4. The CIS (Cytoplasmic) chamber is filled
with 800µL of buffer consisting of 25mM HEPES, and 400mM CsMeSO4 at pH 7.4. The
unequal volumes create equals levels of fluid between the two chambers, reducing any
hydrostatic pressure at the aperture between the two chambers.
Two electrically conducting salt bridges (Agarose, 4 M CsCl) connect the two chambers
to two Ag/AgCl electrodes. The electrodes pass into a preamp which then runs into a
Warner BC-525A amplifier. The amplifier passes its signal into an Axon Instruments
Digidata 1322A digitizer and signals are recorded in Axon software (pClamp 9.0,
ClampEx patch clamp chart recorder).

24

Figure 7 Bilayer Setup

Bilayers
ilayers are formed between the two chambers using the film drainage method31.
A lipid mixture consisting of a 5:3:2 mix of PE:PS:PC (PE: 1,2
1,2-Dioleoyl--sn-Glycero-3Phosphoethanolamine; PS: 1,2
1,2-Dioleoyl-sn-Glycero-3[phosphor-L-Serine];
Serine]; PC: 1,21,2
Dioleoyl-sn-Glycero-3-phosphocholine)
phosphocholine) (AVANTI) is m
made in decane
ecane at a concentration
of 33.3mg/ml. A rounded glass capillary tube is then dipped into the lipid mix and
dragged over the hole separating the two chambers. Two monolayers are formed
separated by a layer of decane between them
them. The pressure from the salt bath causes the
monolayers to form into a bilay
bilayer.
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Formation and quality of the bilayer is determined by tracking the capacitance of the
aperture. Square waves are indicative of good bilayers; a saw tooth capacitance is an
indication of a leak across the bilayer. The bilayer capacitance is also a measure of the
thickness of the bilayer; the capacitance is inversely proportional to the thickness of the
bilayer.

Crude cardiac SR vesicles are homogenized in 300mM Sucrose, 400mM CsMeSO4 and
added to the CIS chamber (final protein concentration: 10-40µg/mL). A holding potential
of +36mV is set, which promotes fusion of SR vesicles. Once fusion occurs, the Trans
bath is brought up to 400mM CsMeSO4 and the holding potential is set at -36mV.
Vesicle fusion occurs in such a way such that the cytoplasmic side of the RyR faces the
Cis chamber32.

When the channel is in an open state, Cs+ ions are able to pass through the channel; the
conductance of the channel is monitored and recorded. Cs+ is used as the current carrying
ion through the channel for several reasons:

•

The conductance of the RyR is higher for Cs+ than Ca2+33.

•

Cs+ does not modulate the channel in the same way that Ca2+ does34.

•

Finally, K+ channels found in the SR are inhibited by high concentrations of
Cs+35; this makes K+ channels distinguishable from RyR channels.

26

Subsequent recordings are made for no less than one minute each. Following each
recording a measured concentration of compound being tested (made up fresh each day)
is added and magnetic stir bars mix the solution for 30 seconds. Each recording of
channel activity at the various compound concentrations is analyzed. The entire bilayer
set-up sits in an aluminum cage to reduce outside noise.

3.2.2 Analysis

3.2.2.1 Event Detection
The Clampfit 9.0 software is mostly automated, the primary analysis tool used in
Clampfit 9.0 is creating an events list using the half-amplitude threshold technique. A
baseline is first set representing the channels closed state; a second level is then set
representing the channel in its open state. In cases where multiple channels are present,
2nd and 3rd open levels may be set. The half-amplitude threshold technique distinguishes
any event that is at least half of the open state level as an open event. Statistical analysis
of the event list is then used to determine properties of the channel.

3.2.2.2 Open Probability
Open probability (P0) of the channel represents the probability of the channel being in the
conducting (open) state. A channel that is in a completely closed state will have a P0 of
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zero, while a channel in a completely open state will have a P0 of 1. P0 is calculated as the
ratio of the total time open to the total time of the recording.

P0 =

T0
T0 + TC

(eqn 3.3)

Where: T0=Nτ0, TC=NτC

3.2.2.3 Open and Closed Dwell Times
A list of dwell times for each level set is generated in the events window. The dwell time
is a representation of the time spent during each event, or the time spend at one level
before changing to a different level. The channel’s P0 depends upon three key factors; the
open dwell time (τO), the closed dwell time (τC), and the frequency of events. It is for this
reason that open and closed times must be analyzed to determine the kinetics of the
gating.

Logarithmic histograms of the number of events vs. the dwell time are generated in the
Clampfit 9.0 software. The histogram is fit to determine average τO and τC times.

3.2.2.4 Student T-Test
A t-test was applied to data for open and closed times between the control and varying
concentrations of tested compound.
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t=

X1 − X 2
1
1
S X 1X 2 ⋅
+
n1 n2

(eqn 3.4)

Where
S X 1X 2 =

(n1 − 1) S X2 1 + (n 2 − 1) S X2 2
n1 + n 2 − 2

(eqn 3.5)

Where n1,n2, SX1, SX2, X1, and X2 are the sample size, standard deviation, and mean
value for the 2 concentrations of compound being compared.

From the t-test p-values between concentrations were calculated. The p-value is a
measure of the statistical significance of the data. Here, a p-value equal or less than .05 is
considered statistically significant.

3.3 Electron Donor/Acceptor Assay
Methylene blue (MB) is a dye that when illuminated with light will produce both dye
anion and a dye cation radicals. Under normal circumstances, with no electron donor or
acceptors present, the dye anion and cation will quickly recombine. If an electron donor
is present, the electrons from the donor will pass to the dye cation, which will in turn
increase the amount of dye anion radical present in the solution. When two dye anions
combine, methylene blue bleaches. When dye anions pass electrons to O2, superoxide is
generated.
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XTT is a compound whose spectrum changes increasing absorbance at 470nm by
reacting with superoxide. The more superoxide that is present, the larger the increased
absorbance at 470nm. With 50µM XTT, varying concentrations of electron donor, 10µM
MB, oxygen, and light, electron donor properties of a given compound can be quantified
by monitoring the spectrum change in XTT, as a function of time.

Figure 8 Schematic showing the process of measuring electron donor/acceptor
properties36

3.4 Ryanodine Binding Assays
Ryanodine is an alkaloid found in the plant Ryania Speciosa. It binds with very high
affinity to the ryanodine receptor, and at low micromolar concentrations, can lock the
channel in a half open state.
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Nanomolar levels of tritium labeled Ryanodine ([3H]ryanodine) bind to the ryanodine
receptor when it is in an open state. This gives it a power of being a strong molecular
probe to assay the open state of the channel. By adding varying concentrations of
inhibitors or activators of the channel, several different assays involving binding of
[3H]ryanodine can be performed.
3.4.1 Initial Rate of Ryanodine Binding
Varying concentrations of either isoproterenol or epinephrine were combined in test tubes
containing: 250mM KCl, 15mM NaCl, 20mM PIPES, 50uM Ca2+, .5mg/mL crude
cardiac SR, 13nM unlabeled ryanodine at pH 7.4. The test tubes were placed in a hot bath
at 37˚C and the reaction is initiated by the addition of 2nM [3H]ryanodine to the test tubes
at varying time points. For isoproterenol, the reaction was terminated at times 5, 10, 15,
20, 25, and 30 minutes. For epinephrine only four time points were used: 5, 10, 15, and
20 minutes.
The reaction was quenched by rapid filtration using a Brandel cell harvester and filtering
through Whatman glass fiber filters. The filters were subsequently washed with a buffer
containing: 250mM KCL, 20mM TRIS, 15mM NaCl, 100uM CaCl2 at pH 7.4. Filters
were placed in an oven at 50˚C for two hours, at which point 3mL of CytoScint
scintillation fluid was added and the solution was agitated for at least 1 hour.
A Beckman LS 6000 scintillation counter was used to measure the levels of
[3H]ryanodine present in each sample. The total activity was measured by adding the
same amount of [3H]ryanodine used in the experiment directly to the scintillation fluid
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and measuring activity. Nonspecific binding was also measured with 200nM unlabeled
ryanodine and 4mM EGTA.
In the initial rate of ryanodine binding assay it is anticipated that inhibitors of the channel
decrease the amount of binding that occurs over a given period of time. Channel
stimulators have the opposite effect; the channel is more open, therefore allowing more
ryanodine binding to occur.

3.4.2 Ca2+-Dependence Ryanodine Binding Assay
Ca2+ dependent ryanodine binding was measured with 10µM isoproterenol following a
similar overall method to the initial rates binding assay. Here, drug concentration is kept
constant and the Ca2+ concentration is varied. A control is also performed with the same
concentrations of Ca2+ but with no drug present. The incubation at 37˚C is carried out for
a period of three house and assaying of the activity is performed the same as the initial
rate assay.
Rise in ryanodine binding can be seen in varying concentrations Ca2+ because Ca2+ is
itself a modulator of the openness of the channel. A compound that is an inhibitor may
shift the Ca2+ dependence of RyR2 so that more Ca2+ will be needed to reach maximal
binding (this would be illustrated by a shift of the curve to the right). A channel activator
may lower the Ca2+ dependence, which can be seen by a shift in the curve to the left. In
RyR2, the Ca2+ dependence is very abrupt, binding goes from a minimum to a maximum
over a very small range of Ca2+ concentrations.
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Chapter IV Results

4.1 Electron Donor Properties of Studied Catecholamines

4.1.1 Isoproterenol Displays Strong Electron Donor Properties
Isoproterenol was assayed for its ability to donate electrons as explained in the methods
section. Concentrations ranging from 0-100µM isoproterenol were tested and the
reduction of XTT vs. time for each concentration was plotted. Figure 9 shows data from a
total of three experiments, averaged and fit to a 2-parameter exponential rise to
maximum:

(

y = c 1 − e − dt

)

(eqn 4.1)

The standard deviation was plotted for each data point from the 3 experiments. The
experiment was performed at pH 7.4 to mimic the condition performed in the planar lipid
bilayer.
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Figure 9 Electron donor properties of isoproterenol
Isoproterenol displays strong electron donor properties in 1mM Tris Buffer at pH 7.4,
containing 10µM MB, and 50µM XTT. Reduction of XTT was measured as an increase
in the absorbance at 470nm. Each data point is an average of 3 experiments ± the
standard deviation.
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4.1.2. Epinephrine Displays Strong Electron Donor Properties
Epinephrine was assayed for its ability to donate electrons as explained in the methods
section. Concentrations ranging from 0-100µM of epinephrine were tested and the
reduction of XTT vs. time for each concentration was plotted. Figure 10 shows data from
a total of three experiments, averaged and fit to a 2-parameter exponential rise to
maximum. The standard deviation was plotted for each data point from the 3
experiments. The experiment was performed at pH 7.4 to mimic the condition performed
in the planar lipid bilayer.
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Figure 10 Electron donor properties of epinephrine
Epinephrine displays strong electron donor properties in 1mM Tris Buffer at pH 7.4,
containing 10µM MB, and 50µM XTT. Reduction of XTT was measured as an increase
in the absorbance at 470nm. Each data point is an average of 3 experiments ± the
standard deviation.
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4.1.3. Comparison of Electron Donor Properties
The initial rates of XTT reduction were calculated using the 2-parameter exponential rise
along with the values of c and d generated from eqn. 4.1 in SigmaPlot 9.0. The initial
rates vs. concentration of concentrations for both isoproterenol and epinephrine were
plotted in figure 11, and fitted to the Michaelis-Menten equation.

V =

Vmax [S ]
K d + [S ]

(eqn 4.2)

Where: V=reaction rate, [S]=substrate concentration, Vmax=maximum rate, and Kd=the
concentration at half maximal rate.
Standard error for the initial rate was calculated and plotted for each data point. The two
donors show very similar strengths; half maximal donor activities were calculated from
the fit for epinephrine and isoproterenol to be 17.5µM and 24.3µM respectively.
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Figure 11 Comparison of the electron donor properties of epinephrine and
isoproterenol
1mM Tris buffer, containing 10µM MB, 50µM XTT at pH 7.4. Initial rates of XTT
reduction were calculated and plotted using a 4-parameter logistic fit. Each point
represents 3 experiments averaged ± the standard deviation.
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4.2 RyR2 Inhibition by Isoproterenol
Isoproterenol’s effect on RyR2 was tested in the planar lipid bilayer. All experiments
were done in the presence of 410nM Ca2+ (calculated from Bound and Determined,
BAD). Isoproterenol was tested in a dose dependent manner ranging in concentrations of
100nM-7uM. A total of 8 experiments were performed under identical conditions.
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Figure 12 Representative single channel recordings of isoproterenol
Two second representative traces of RyR2 inhibition by isoproterenol. A channel opening
is indicated by a downward fluctuation. A) 410nM Ca2+ (P0=0.50) B) 100nM
Isoproterenol (P0=0.44) C) 300nM Isoproterenol (P0=0.26) D) 500nM Isoproterenol
(P0=0.11) E) 1µM Isoproterenol (P0=0.06)
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Figure 13 shows the concentration-dependent inhibition of single channel activity
induced by isoproterenol. Normalized P0 was plotted vs. isoproterenol concentration. A
4-parameter logistic plot was used to fit the data:

y = y0 +

a
 x
1 + 
 x0





b

(eqn 4.3)

The IC50 from the fit was determined to be 210nM. The IC50 is a measure of the
compounds potency as a channel inhibitor; it represents the concentration at which the
channel is half maximally inhibited. As can be seen from figure 13, the channel was
never able to be fully closed by isoproterenol, making isoproterenol a partial antagonist
of RyR2.
Ruthenium Red (R.R.), an inorganic dye that has been shown to completely block the
ryanodine receptor when added to its cytoplasmic face, was added at the termination of
each experiment when channel activity was still present. This is to ensure that the
cytoplasmic face is facing the Cis chamber, as well as to ensure that the gating being
observed is the ryanodine receptor and not some other ion channel present in the SR. In
all of these experiments, 10µM R.R. decreases the P0 to zero.
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Figure 13 RyR2 inhibition by Isoproterenol
Control recordings at 410nM Ca2+ were normalized to 1. Average P0 with standard error
before normalization was 0.50±0.06. Each point represents the average of 8 experiments
± standard error.
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4.3 RyR2 Inhibition by Epinephrine
Planar lipid bilayer experiments were performed to test Epinephrine’s potency on RyR2.
410nM free Ca2+ was used (calculated using BAD). Epinephrine concentrations ranging
from 100nM-30uM were tested in a total of 6 experiments. Standard error bars were
generated and the IC50 value was determined using the same method as used for
isoproterenol.

43

C

A

O1

O2

C

O1

B

O2
O2

C
C

O1

C

O1

D

C
E
O1
30 pA
200ms

Figure 14 Representative single channel recordings of epinephrine
Two second traces showing dose-dependent inhibition by epinephrine. Two
channels can be distinctly identified in traces A and B. A channel opening is indicated by
a downward fluctuation. A) 410nM Ca2+ (P0=1.3) B) 1µM Epinephrine (P0=0.88) C)
3µM Epinephrine (P0=0.40) D) 5µM Epinephrine (P0=0.23) E) 10µM Epinephrine
(P0=0.15)
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Figure 15 shows the dose-dependent response of normalized RyR2 open probability vs.
epinephrine concentration. Like isoproterenol, epinephrine displays strong inhibition of
RyR2 characteristics. The IC50 was determined to be 310nM. Epinephrine at high
concentrations (30µM) is more effective in inhibiting channel activity than is
isoproterenol. However, neither compound completely closes down the channel. They are
both partial antagonists of RyR2 activity. Once again, 10µM RR was added at the
termination of each experiment.
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Figure 15 RyR2 inhibition by epinephrine
Control recordings at 410nM Ca2+ were normalized to 1. Average P0 with standard error
before normalization was 0.56±0.09. Each point represents the average of 6 experiments
± standard error.
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4.4 Dwell Times

4.4.1 Isoproterenol Increases the Closed Time of RyR2
Open and closed dwell times were calculated for isoproterenol as described in the
methods section. Figure 16 shows normalized open times for varying concentrations of
isoproterenol; open time decreases slightly. The p-values at 500nM and5µM
isoproterenol for the open time were determined to be 0.14 and 0.08 respectively,
indicating a statistically insignificant result. However, fluctuations in the open time are
hard to measure due to the already short open time of control recordings (∿1ms) and the
resolution to which they can be measured; this leaves a level of uncertainty as to whether
the measurements made in this experiment for the open times actually reflect the open
time of the channel.
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Figure 16 Open times of RyR2 with isoproterenol
Open time (τO) of single channel measurements at varying concentrations of
isoproterenol. Isoproterenol slightly lowers the open time of the channel. Control
recordings (410nM Ca2+) were normalized to one. Average τ0 with standard error (n=7)
prior to normalization was 1.15±0.22 ms. All data is the average of 7 experiments
normalized as the percent of control ± the standard error.
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Figure 17 shows the normalized closed times as a function of isoproterenol. Closed time
dramatically increases as increasing concentrations of isoproterenol is added. This means
that isoproterenol’s inhibition of RyR2 is mainly due to an increase in the closed time of
the channel. The p-values at 500nM and 5µM isoproterenol were determined to be 0.02
and 0.01 respectively, making the epinephrine’s effect of increasing the closed durations
statistically significant.
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Figure 17 Closed times of RyR2 with isoproterenol
Closed times of single channel measurements at varying concentrations of isoproterenol.
Isoproterenol mainly decreases the open probability by increasing the closed time (τC).
Control recordings (410nM Ca2+) were normalized to one. Average τC with standard error
(n=7) prior to normalization was 2.35±0.47 ms All data is the average of 7 experiments
normalized as the percent of control ± the standard error.
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4.4.2 Epinephrine Increases the Closed Time of the Channel
Epinephrine open and closed times were calculated in the same way as isoproterenol.
Figure 18 shows a slight decrease in the open times as epinephrine concentration
increases. The p-values at 500nM and 5µM epinephrine for the open time were
determined to be 0.41 and 0.18 respectively, indicating a statistically insignificant result.
Once again, these measurements are at the time resolution limit of our setup, so it is
unclear if this data reflects actual open times.
Figure 19 shows that like isopoterenol, epinephrine mainly decreases the open probability
of the channel by increasing the amount of time the channel is in the closed state. The pvalues at 500nM and 5µM epinephrine were determined to be 0.04 and 0.02 respectively,
making the epinephrine’s effect of increasing the closed durations statistically significant.
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Figure 18 Open times of RyR2 with epinephrine
Open times of single channel measurements at varying concentrations of epinephrine.
Epinephrine slightly lowers the open time (τ0) of the channel. Control recordings (410nM
Ca2+) were normalized to one. Average τ0 with standard error (n=5) prior to normalization
was 0.97±0.13 ms All data is the average of 5 experiments normalized as the percent of
control ± the standard error.

52

25

Normalized Closed Time

20

15

10

5

0
0

2

4

6

8

10

Concentration of Epinephrine (µM)
Figure 19 Closed times of RyR2 with epinephrine
Closed times (τC) of single channel measurements at varying concentrations of
epinephrine. Epinephrine mainly decreases the open probability by increasing the closed
time. Control recordings (410nM Ca2+) were normalized to one. Average τC with standard
error (n=5) prior to normalization was 1.78±0.45 ms All data is the average of 5
experiments normalized as the percent of control ± the standard error.
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4.5 Ryanodine Binding is Unaffected by Isoproterenol and Epinephrine
Initial rate experiments were performed for both isoproterenol and epinephrine as
described in the methods section. Despite both compounds being strong inhibitors of
RyR2 at the single channel level, they display no strong trends in the inhibition or
stimulation in the initial rates of ryanodine binding.
As can be seen in figure 20, the rate of ryanodine binding is not sensitive to the
isoproterenol concentration. All concentration tested start and end at roughly the same
level as the control experiment (50µM Ca2+, no drug). This indicates that the channels
remained in roughly the same open percentage for all concentrations of isoproterenol as
well as the control.
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Figure 20 Isoproterenol does not affect the rate of ryanodine binding
Initial rate of ryanodine binding vs. isoproterenol concentration. No significant changes
in the amount of ryanodine binding over time are observed as a function of
[isoproterenol].
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Figure 21 shows a similar trend for epinephrine compared to that seen with isoproterenol.
The amount of binding increased in a linear manner over the 4 time points used. All
traces roughly start and end at the same point as the control (50µM Ca2+, no drug). Once
again, this is indicative of epinephrine of having no inhibitory effect on ryanodine
binding.
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Figure 21 Epinephrine does not affect the rate of ryanodine binding
Initial rate of ryanodine binding vs. epinephrine concentration. No significant changes in
the amount of ryanodine binding over time are observed as a function of [epinephrine].
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In addition to the initial rates experiments, a Ca2+ dependence experiment was carried out
both with and without 10µM isoproternol. Figure 22 shows a sharp rise of ryanodine
binding over a small range of Ca2+ concentrations for both traces. There is no significant
shift of the curve between the control and the 10µM isoproterenol. This is once again
indicative of isoproterenol not having an effect on the openness of the channel in
ryanodine binding type experiments.
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Figure 22 Isoproterenol Ca2+ dependent ryanodine binding
Ca2+-dependence equilibrium binding with and without 10µM isoproterenol. No
significant shift in the Ca2+-dependence can be seen.
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Chapter V Conclusions and Discussion

The role of catecholamies has been studied since the early 1900s and their function in the
body is thought to be well understood. In this thesis, the effect of two catecholamines,
epinephrine and isoproterenol, acting directly upon cardiac ryanodine receptor has been
examined for the first time.
We have shown that both isoproterenol and epinephrine act as strong electron donors.
The concentrations at which epinephrine and isoproterenol half maximally act as electron
donors are 17.5µM and 24.3µM respectively. We have also shown that these two
compounds are potent inhibitors of single channels in the planar lipid bilayer. Bilayer
studies performed produced IC50 values for epinephrine and isoproterenol of 310nM and
210nM respectively. We have shown that the primary means of inhibition is an increase
in the overall closed time of the channel. P-values calculated around and much higher
than the IC50, yielded statistically significant results for the closed times. It is unclear
whether these compounds also have an effect on the open time of the channel. P-values
calculated for the open times yielded non-significant results, but measurements are being
made at the time resolution our system.
It has previously been shown that inhibitors of the ryanodine receptor tend to act as
electron donors, while activators of the channel tend to be electron acceptors37. Here, this
hypothesis is confirmed for the two compounds studied. Both compounds share very
similar electron donor properties as well as similar inhibition of RyR2 in the planar lipid
bilayer.
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These compounds, although strong inhibitors in the bilayer, had no effect on ryanodine
binding experiments. Initial rates of binding indicated that the channels remained in
roughly the same open percentage over all concentrations assayed. This is not the first
time our lab has encountered this apparent dilemma; prior compounds tested, which have
shown strong potency in the bilayer have had no effect on ryanodine binding.
One possible explanation to account for this is the means by which these catecholamines
inhibit the channel. Ryanodine binds to the channel when it is in an open state. We have
shown that these compounds do not significantly impact the duration of the open time of
the channel. It is possible that without significantly altering the open time of the channel,
the total amount of ryanodine binding will remain a constant. Inhibition of ryanodine
binding may require a significant decrease in the open time of the channel.
In the body, catecholamines activate the ryanodine receptor via a non-direct interaction
that is initiated outside of the cell. Epinephrine is hydrophilic, making it unlikely that it is
able to cross the hydrophobic plasma membrane. Isoproterenol, which is not naturally
produced, is also hydrophilic. This indicates that is unlikely that epinephrine or
isoproterenol have a direct interaction on RyR2 when administered, or produced in the
body.
It is known that heart failure is associated with a RyR2 leak thought to be caused by a
hyperphosphorylation of the channel37. This hyperphosphorylation hypotheis remains
controversial; it has been shown that PKA-phosphorylation doesnot affect Ca2+ sparks in
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permeabilized myocytes38. Regardless, β-adrenergic receptor stimulation does seem to
initiate a release of Ca2+ from RyR2, which in turn can lead to arrhythmia.
Two therapeutic ways to treat patients with arrhythmia can be imagined to alleviate a
leaky RyR2; one where a direct interaction with a compound and the β-adrenergic
receptor is utilized to prevent the catecholamines from binding; this is realized with the
advent of the so called “β-blockers.” And a second method, where a direct interaction
between a compound and RyR2 occurs, one that stabilizes the channel into a more closed
state, thereby preventing Ca2+ leak.
β-blockers are high affinity compounds which bind to the β-adrenergic receptor, but do
not stimulate adenyl-cylcase activity. When bound, they will prevent agonists of the βadrenergic receptor, such as the catecholamines, from binding. It has been shown that
treatment with β-blockers can restore cardiac function, reducing the death rate of patients
with HF39. Some such β-blockers being used in the treatment of heart failure include:
Carvedilol, propranolol, metoprolol, and atenolol.
The other method to decrease diastolic Ca2+ leak during arrhythmias is to directly inhibit
the intracellular Ca2+ leak by inhibiting RyR2. It has previously been shown that
compounds such as flecainide40, or benzothiazepine41 will inhibit RyR2, suppressing
arrhythmias in canine and Langendorff rat hearts.
Despite these two method’s ability to alleviate arrhythmia, it is unclear how these
mechanisms are beneficial to heart failure; in normal hearts, inhibition of RyR2 and the
blockade of the β-adrenergic receptor both lead to a decrease in cardiac output. It has
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been proposed that the β-blocker carvedilol functions not only by binding to the βadregnergic receptor, thereby down-regulating PKA activity, but it also directly inhibits
RyR2. Specifically, carvedilol has been shown to suppress spontaneous calcium waves,
also known as stored overload-induced Ca2+ release (SOICR), at concentrations42 similar
to what we show the catecholamines inhibit RyR2 activity.
Both the catecholamines and carvedilol are interesting compounds in that they can
influence RyR2 activity, both on the cell membrane and on RyR2 itself. Carvedilol is
known to cross the cell membrane43, but it is unlikely that it accumulates to levels within
the cell that can inhibit RyR2 activity. The catecholamines neither cross the cell
membrane, nor are present in high enough concentrations in the body to directly
influence RyR2 activity.
Despite the problems with these 2 sets of compounds, this research does offer a
promising insight into the potential development of a new class of compounds. The
alteration of drugs like the catecholamines or carvedilol may lead to the production of a
mored lipophilic compound, one that can both inhibit β-adrenergic receptor activity, and
exist in intracellular concentrations high enough to influence RyR2 activity. Our data
suggests that making these compounds into better electron donors can alleviate the
necessity of increasing the amount of compound needed to inhibit RyR2.
Whether it is possible to modify these compounds without altering the desired effects on
the system remains to be unseen. Regardless, the development of compounds that can
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both inhibit RyR2 activity inside the cell, and act as β-blockers could create a new
frontier in drug development in the prevention of arrhythmia and HF.

64

References:

1

Lehninger, Principles of Biochemistry, 5th ed., n.d.

2

A F Dulhunty et al., “Ion channels in the sarcoplasmic reticulum of striated muscle,”

Acta physiologica Scandinavica 156, no. 3 (March 1996): 375–385.
3

T Imagawa et al., “Purified ryanodine receptor from skeletal muscle sarcoplasmic

reticulum is the Ca2+-permeable pore of the calcium release channel,” The Journal of
biological chemistry 262, no. 34 (December 5, 1987): 16636–16643.
4

I I Serysheva et al., “Electron cryomicroscopy and angular reconstitution used to

visualize the skeletal muscle calcium release channel,” Nature structural biology 2,
no. 1 (January 1995): 18–24.
5

Xiaojun Huang et al., “Calmodulin Binding Locations on the Skeletal and Cardiac

Ryanodine Receptors,” Journal of Biological Chemistry (July 6, 2012),
doi:10.1074/jbc.M112.383109.
6

Elena V. Orlova et al., “Two Structural Configurations of the Skeletal Muscle

Calcium Release Channel,” Nature Structural & Molecular Biology 3, no. 6 (June
1996): 547–552, doi:10.1038/nsb0696-547.
7

T Jayaraman et al., “FK506 binding protein associated with the calcium release

channel (ryanodine receptor),” The Journal of biological chemistry 267, no. 14 (May
15, 1992): 506.
8

A B Brillantes et al., “Stabilization of calcium release channel (ryanodine receptor)

function by FK506-binding protein,” Cell 77, no. 4 (May 20, 1994): 513–523.

65

9

J S Smith, E Rousseau, and G Meissner, “Calmodulin modulation of single

sarcoplasmic reticulum Ca2+-release channels from cardiac and skeletal muscle,”
Circulation research 64, no. 2 (February 1989): 352–359.
10

Huang et al., “Calmodulin Binding Locations on the Skeletal and Cardiac

Ryanodine Receptors.”
11

L Zhang et al., “Complex formation between junctin, triadin, calsequestrin, and the

ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum
membrane,” The Journal of biological chemistry 272, no. 37 (September 12, 1997):
23389–23397.
12

D H MacLennan and P T Wong, “Isolation of a calcium-sequestering protein from

sarcoplasmic reticulum,” Proceedings of the National Academy of Sciences of the
United States of America 68, no. 6 (June 1971): 1231–1235.
13

Michael J Jurynec et al., “Selenoprotein N is required for ryanodine receptor

calcium release channel activity in human and zebrafish muscle,” Proceedings of the
National Academy of Sciences of the United States of America 105, no. 34 (August 26,
2008): 12485–12490, doi:10.1073/pnas.0806015105.
14

G Meissner, E Darling, and J Eveleth, “Kinetics of rapid Ca2+ release by

sarcoplasmic reticulum. Effects of Ca2+, Mg2+, and adenine nucleotides,”
Biochemistry 25, no. 1 (January 14, 1986): 236–244.
15

Chris Jalilian et al., “Redox potential and the response of cardiac ryanodine

receptors to CLIC-2, a member of the glutathione S-transferase structural family,”

66

Antioxidants & redox signaling 10, no. 10 (October 2008): 1675–1686,
doi:10.1089/ars.2007.1994.
16

Meissner, Darling, and Eveleth, “Kinetics of rapid Ca2+ release by sarcoplasmic

reticulum. Effects of Ca2+, Mg2+, and adenine nucleotides.”
17

Véronique L. Roger et al., “Heart Disease and Stroke Statistics—2012 Update A

Report From the American Heart Association,” Circulation 125, no. 1 (January 3,
2012): e2–e220, doi:10.1161/CIR.0b013e31823ac046.
18

JA Thomas and BH Marks, American Journal of Cardiology 41 (1978): 233–243.

19

C L Antos et al., “Dilated cardiomyopathy and sudden death resulting from

constitutive activation of protein kinase a,” Circulation research 89, no. 11
(November 23, 2001): 997–1004.
20

Bailong Xiao et al., “Protein kinase A phosphorylation at serine-2808 of the

cardiac Ca2+-release channel (ryanodine receptor) does not dissociate 12.6-kDa
FK506-binding protein (FKBP12.6),” Circulation research 94, no. 4 (March 5, 2004):
487–495, doi:10.1161/01.RES.0000115945.89741.22.
21

Steven O. Marx et al., “Phosphorylation-Dependent Regulation of Ryanodine

Receptors,” The Journal of Cell Biology 153, no. 4 (May 14, 2001): 699–708.
22

S O Marx et al., “PKA phosphorylation dissociates FKBP12.6 from the calcium

release channel (ryanodine receptor): defective regulation in failing hearts,” Cell
101, no. 4 (May 12, 2000): 365–376.

67

23

G Hasenfuss et al., “Relationship between Na+-Ca2+-exchanger protein levels and

diastolic function of failing human myocardium,” Circulation 99, no. 5 (February 9,
1999): 641–648.
24

A. M. Gómez et al., “Defective Excitation-Contraction Coupling in Experimental

Cardiac Hypertrophy and Heart Failure,” Science 276, no. 5313 (May 2, 1997): 800–
806, doi:10.1126/science.276.5313.800.
25

R.J. Merrills and J. Offerman, “The Synthesis of Noradrenaline by Isolated Guinea-

Pig Atria,” Journal of Biochemistry 99, no. 538 (November 8, 1965).
26

Toshiharu Nagatsu, Biochemistry of Catecholamines, 1973.

27

L R Krakoff et al., “Plasma epinephrine concentration in healthy men: correlation

with systolic pressure and rate-pressure product,” Journal of the American College of
Cardiology 5, no. 2 Pt 1 (February 1985): 352–356.
28

R Sitsapesan and A J Williams, “Mechanisms of Caffeine Activation of Single

Calcium-release Channels of Sheep Cardiac Sarcoplasmic Reticulum.,” The Journal of
Physiology 423 (April 1990): 425–439.
29

M. Kalckar, “Differential Spectrophotometry of Purine Compounds by Means of

Specific Enzymes,” Journal of Biological Chemistry no. 167 (1947): 461–475.
30

W F Wonderlin, A Finkel, and R J French, “Optimizing Planar Lipid Bilayer Single-

channel Recordings for High Resolution with Rapid Voltage Steps.,” Biophysical
Journal 58, no. 2 (August 1990): 289–297.

68

31

Paul Mueller et al., “Reconstitution of Excitable Cell Membrane Structure in Vitro,”

Circulation 26, no. 5 (November 1, 1962): 1167–1171,
doi:10.1161/01.CIR.26.5.1167.
32

C Miller and E Racker, “Ca++-induced fusion of fragmented sarcoplasmic

reticulum with artificial planar bilayers,” The Journal of membrane biology 30, no. 3
(1976): 283–300.
33

D R Laver et al., “Cytoplasmic Ca2+ inhibits the ryanodine receptor from cardiac

muscle,” The Journal of membrane biology 147, no. 1 (September 1995): 7–22.
34

G Meissner et al., “Regulation of skeletal muscle Ca2+ release channel (ryanodine

receptor) by Ca2+ and monovalent cations and anions,” The Journal of biological
chemistry 272, no. 3 (January 17, 1997): 1628–1638.
35

S Cukierman, G Yellen, and C Miller, “The K+ Channel of Sarcoplasmic Reticulum. A

New Look at Cs+ Block.,” Biophysical Journal 48, no. 3 (September 1985): 477–484.
36

Benjamin S Marinov et al., “Non-thiol reagents regulate ryanodine receptor

function by redox interactions that modify reactive thiols,” Antioxidants & redox
signaling 9, no. 5 (May 2007): 609–621, doi:10.1089/ars.2006.1426.
37

Steven Reiken et al., “β-Blockers Restore Calcium Release Channel Function and

Improve Cardiac Muscle Performance in Human Heart Failure,” Circulation 107, no.
19 (May 20, 2003): 2459–2466, doi:10.1161/01.CIR.0000068316.53218.49.

69

38

Yanxia Li et al., “Protein kinase A phosphorylation of the ryanodine receptor does

not affect calcium sparks in mouse ventricular myocytes,” Circulation research 90,
no. 3 (February 22, 2002): 309–316.
39

Michael R. Bristow, “β-Adrenergic Receptor Blockade in Chronic Heart Failure,”

Circulation 101, no. 5 (February 8, 2000): 558–569, doi:10.1161/01.CIR.101.5.558.
40

Fredrick A. Hilliard et al., “Flecainide Inhibits Arrhythmogenic Ca2+ Waves by

Open State Block of Ryanodine Receptor Ca2+ Release Channels and Reduction of
Ca2+ Spark Mass,” Journal of Molecular and Cellular Cardiology 48, no. 2 (February
2010): 293–301, doi:10.1016/j.yjmcc.2009.10.005.
41

Mark D. McCauley and Xander H. T. Wehrens, “Targeting Ryanodine Receptors for

Anti-arrhythmic Therapy,” Acta Pharmacologica Sinica 32, no. 6 (June 2011): 749–
757, doi:10.1038/aps.2011.44.
42

Qiang Zhou et al., “Carvedilol and its new analogs suppress arrhythmogenic store

overload-induced Ca2+ release,” Nature medicine 17, no. 8 (August 2011): 1003–
1009, doi:10.1038/nm.2406.
43

A Hjalmarson, “Cardioprotection with beta-adrenoceptor blockers. Does

lipophilicity matter?,” Basic research in cardiology 95 Suppl 1 (2000): I41–45.

70

